Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin lymfoma
| Autoři | |
|---|---|
| Rok publikování | 2005 |
| Druh | Konferenční abstrakty |
| Fakulta / Pracoviště MU | |
| Citace | |
| Popis | Introduction: Depending on the type of the chemotherapy (CT) administered, premature ovarian failure develops in young women, causing clinical symptoms due to the lack of estrogens, and resulting in subsequent sterility. Objectives: Retrospective analysis of the fertility was made in female pts treated with the BEACOPP or ABVD and MOPP(COPP),ABVD CT. Methods: A total of 16 pts underwent the therapy based on the BEACOPP with baseline (n=6) or escal. doses (n=4), or a combination of 4 cycles of the baseline and escal. BEACOPP (n=6). A total of 32 pts were treated with CT in the past, namely using the ABVD (n=25) or the hybrid MOPP(COPP),ABVD alternating regimen (n=7). Results: 5/16 (31 %) of the pts reported oligomenorrhoea or complete amenorrhoea during the BEACOPP. After 6 months from the end of the therapy, half of the pts (n=8) did not menstruate. The menses disappeared during the ABVD or MOPP (COPP)/ABVD in 6/36 (19 %) of the pts. Conclusions: The BEACOPP poses a risk of early menopause and permanent sterility to young patients owing to the presence of several gonadotoxic agents. |